PyInvesting

Market research

PACB Pacific Biosciences of California

NASDAQ USD Healthcare

Latest close

2.605 —

As of 30 Oct 2026

Test a moving-average rule with historical data.

Market facts
Market cap
538M
P/E ratio
Not available
Analyst target
2.4
Dividend yield
Not available
Beta
2.19

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 6 months ago

Pacific Biosciences of California, Inc is currently in a long term uptrend where the price is trading 14.8% above its 200 day moving average.

From a valuation standpoint, the stock is 94.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 76.6.

Pacific Biosciences of California, Inc's total revenue sank by 2.8% to $27M since the same quarter in the previous year.

Its net income has increased by 82446.2% to $75M since the same quarter in the previous year.

Finally, its free cash flow grew by 21.8% to $-14M since the same quarter in the previous year.

Based on the above factors, Pacific Biosciences of California, Inc gets an overall score of 4/5.